BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine
BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine
萬春醫藥在ISLAC 2024上發佈了Plinabulin在2L/3L非小細胞肺癌的最終3期結果，並同時在《柳葉刀呼吸醫學》雜誌上發表了相關文章。
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC after Progression on Platinum-based Therapy
- Plinabulin/Docetaxel Combination Significantly Improved Overall Survival (OS), Progression Free Survival (PFS), Objective Response Rate (ORR), 2- and 3-year OS Rates and Significantly Reduced Grade 4 Neutropenia vs. Docetaxel
- 在鉑金爲基礎的治療後，Plinabulin加Docetaxel與Docetaxel在EGFR野生型非小細胞肺癌患者上的DUBLIN-3第3期研究中有統計學顯著而臨床意義明顯的療效數據，並且有良好的效益/風險比。
- Plinabulin/Docetaxel聯合治療明顯改善了總生存期（OS），無進展生存期（PFS），目標反應率（ORR），2年和3年的OS率，並且與Docetaxel相比顯著降低了4級中性粒細胞減少症的發生率。
資訊熱榜
更新時間